Last update 21 Nov 2024

Lucitanib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lucitanib (USAN/INN)
+ [3]
Mechanism
FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists)
+ [2]
Login to view timeline

Structure

Molecular FormulaC26H25N3O4
InChIKeyCUDVHEFYRIWYQD-UHFFFAOYSA-N
CAS Registry1058137-23-7

External Link

KEGGWikiATCDrug Bank
D11762Lucitanib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Colonic CancerPhase 3
CN
30 Jan 2022
Colonic CancerPhase 3
CN
30 Jan 2022
Small Cell Lung CancerPreclinical
CN
14 Nov 2019
Breast CancerPreclinical
CA
--
Breast CancerPreclinical
HU
--
Breast CancerPreclinical
GB
--
Breast CancerPreclinical
DE
--
Breast CancerPreclinical
ES
--
Extensive stage Small Cell Lung CancerDiscovery
CN
14 Nov 2019
Small Cell Lung CancerDiscovery
CN
14 Nov 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
25
(Arm A1: Rucaparib 300 mg BID and Lucitanib 4 mg QD)
qevhtweipo(tvfergmsyn) = cpnjotbvdf ehxobrhcqf (znbqydhtrb, spiqlrgjfz - wkxvzlxdct)
-
16 Jan 2024
(Arm A2: Rucaparib 400 mg BID and Lucitanib 4 mg QD)
qevhtweipo(tvfergmsyn) = wzbpoizwti ehxobrhcqf (znbqydhtrb, wvsiamuqbk - qdungdptho)
Phase 2
124
Lucitanib 6 mg QD + Nivolumab 480 mg every 28 days
(itlsnwilfk) = Grade ≥3 treatment-emergent adverse events (TEAEs) considered study-treatment related were reported in 55 (44.4%) patients, with the most frequent being hypertension (n=30 [24.2%]) pikmiocvqq (hxsiyddrcb )
Positive
20 Oct 2022
Not Applicable
-
(clkowvimdm) = 1 patient discontinued lucitanib due to a related TEAE (colonic fistula) sxzvvghqok (bzfyvxdnvk )
-
01 Aug 2022
Phase 1
44
(continuous arm)
(kwzhvveyhx) = tdonqtikqs rqerfdztdj (ndvrvzcowo )
Positive
08 Jun 2022
(intermittent arms)
(kwzhvveyhx) = duxxpmvrck rqerfdztdj (ndvrvzcowo )
Phase 2
100
(endometrial cancer)
(ejlngltewe) = Eleven (11%) and 8 (8%) pts discontinued lucitanib and nivolumab, respectively, due to a treatment-related TEAE. dsgziwdknz (wqgzxcesjj )
Positive
02 Jun 2022
(cervical cancer)
Phase 1/2
17
nivolumab+Lucitanib
(yvgzjgptcp) = skauijlwjp noikkqiiez (jyztsvwkdk )
Positive
28 May 2021
Phase 1/2
16
(altjulwidy) = nausea (n=9; grade ≥3, n=1), hypertension (n=8; grade ≥3, n=2) and ALT/AST increased (n=7; grade ≥3, n=3) slytdcdhvv (drnoebvufw )
Positive
20 May 2021
Phase 2
15
(islzeiqubc) = In the first cohort of 4 pts evaluating 6 mg, 1 DLT (Grade [G]3 proteinuria) was observed, leading to discontinuation. This pt also experienced G3 hypertension (HTN), G2 fatigue and G1 oedema. mnywxuuscv (ydqypyetwf )
Positive
17 Sep 2020
Phase 1
44
(nfcscupsqs) = 3 pts (13.6%) and 1 pt (4.5%) in CON and INT respectively sldcwwwnhx (vnuccknrzy )
-
25 May 2020
Not Applicable
-
-
qsrvnlpewu(pexogcoiee) = ocpfzajute eafoktcszk (hoomgcmvgp )
Positive
01 Nov 2019
DC101 40 mg/kg
qsrvnlpewu(pexogcoiee) = exhrpjppeq eafoktcszk (hoomgcmvgp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free